DOP2012000188A - Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus metodos de empleo - Google Patents
Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus metodos de empleoInfo
- Publication number
- DOP2012000188A DOP2012000188A DO2012000188A DO2012000188A DOP2012000188A DO P2012000188 A DOP2012000188 A DO P2012000188A DO 2012000188 A DO2012000188 A DO 2012000188A DO 2012000188 A DO2012000188 A DO 2012000188A DO P2012000188 A DOP2012000188 A DO P2012000188A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- compositions
- methods
- certain
- triazolopiridines
- triazolopirazines
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000008523 triazolopyridines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009076321 | 2009-12-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2012000188A true DOP2012000188A (es) | 2012-12-31 |
Family
ID=44226181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2012000188A DOP2012000188A (es) | 2009-12-31 | 2012-06-29 | Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus metodos de empleo |
Country Status (38)
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3511330T (pt) * | 2009-12-31 | 2020-12-24 | Hutchison Medipharma Ltd | Intermediário sintético útil na preparação de inibidores de triazolopiridina c-met |
| JP5960688B2 (ja) | 2010-05-17 | 2016-08-02 | インコゼン セラピューティクス プライベート リミテッド | プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物 |
| CN103030654A (zh) * | 2011-10-09 | 2013-04-10 | 济南赛文医药技术有限公司 | 一种小分子c-Met蛋白激酶抑制剂 |
| CN102516046A (zh) * | 2011-11-22 | 2012-06-27 | 太仓市运通化工厂 | 一种2-溴丙醛的合成方法 |
| CN104321322A (zh) * | 2012-03-30 | 2015-01-28 | 理森制药股份公司 | 作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物 |
| CA2776178A1 (en) * | 2012-04-05 | 2013-10-05 | Hydro-Quebec | Ionic compounds |
| KR101745741B1 (ko) | 2012-08-13 | 2017-06-12 | 한국화학연구원 | 신규한 트리아졸로 피라진 유도체 및 그의 용도 |
| BR112015016580A2 (pt) | 2013-01-11 | 2017-07-11 | Fujifilm Corp | composto heterocíclico contendo nitrogênio ou sal deste |
| LT2964638T (lt) | 2013-03-06 | 2017-12-27 | Astrazeneca Ab | Epidermio augimo faktoriaus receptoriaus aktyvinančių mutacijų formų chinazolino inhibitoriai |
| CN103265468A (zh) * | 2013-06-17 | 2013-08-28 | 连云港盛和生物科技有限公司 | 一种2,4-二甲基-3-吡咯甲酸乙酯的合成方法 |
| EP2818471A1 (en) * | 2013-06-27 | 2014-12-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5 |
| AU2013402175B2 (en) * | 2013-09-30 | 2017-09-07 | Handok Inc. | Novel triazolopyrazine derivative and use thereof |
| PL3087070T3 (pl) * | 2013-12-26 | 2018-03-30 | Ignyta, Inc. | Pochodne pirazolo[1,5-a]pirydyny i sposoby ich zastosowania |
| JP2016048495A (ja) * | 2014-08-28 | 2016-04-07 | 京セラ株式会社 | 携帯端末、レコメンドプログラム、レコメンドシステムおよびレコメンド方法 |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| ES2877799T3 (es) * | 2015-12-31 | 2021-11-17 | Shanghai Pharmaceuticals Holding Co Ltd | Sal de derivado de quinolina, formas polimórficas de la misma, métodos de preparación de la misma, composición y aplicaciones |
| GB201616116D0 (en) | 2016-09-22 | 2016-11-09 | Astrazeneca Ab | Use of c-Met inhibitors to treat cancers harbouring MET mutations |
| KR20180092096A (ko) | 2017-02-08 | 2018-08-17 | 에이비온 주식회사 | 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법 |
| CA3053818A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
| WO2018160892A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| CN108570053A (zh) * | 2017-03-13 | 2018-09-25 | 中国科学院上海药物研究所 | 五元并六元杂环化合物、制备方法、中间体、组合和应用 |
| KR101924801B1 (ko) | 2017-08-16 | 2018-12-04 | 한국원자력의학원 | 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물 |
| HU231333B1 (hu) | 2018-07-13 | 2023-01-28 | Richter Gedeon Nyrt | Spirokromán származékok |
| HU231414B1 (hu) | 2018-07-13 | 2023-08-28 | Richter Gedeon Nyrt. | Tiadiazin származékok |
| JP7443375B2 (ja) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 医学的障害の治療のための大環状化合物 |
| WO2020051538A1 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| AU2019340569B2 (en) * | 2018-09-11 | 2022-06-09 | Astrazeneca Ab | Improved method for the manufacture of 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof |
| WO2020069024A1 (en) | 2018-09-25 | 2020-04-02 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| KR20210097124A (ko) * | 2018-10-30 | 2021-08-06 | 리페어 세라퓨틱스 인크. | 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법 |
| WO2020124060A1 (en) | 2018-12-14 | 2020-06-18 | Beta Pharma, Inc. | Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof |
| CN113195472A (zh) | 2018-12-17 | 2021-07-30 | 艾其林医药公司 | 用于治疗补体介导的病症的靶向给药 |
| MX2021011507A (es) | 2019-03-22 | 2021-12-15 | Achillion Pharmaceuticals Inc | Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento. |
| KR20220035925A (ko) * | 2019-07-22 | 2022-03-22 | 리페어 세라퓨틱스 인크. | Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체 |
| JP2023515073A (ja) * | 2020-02-20 | 2023-04-12 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体因子ｄ媒介障害の処置用のヘテロアリール化合物 |
| WO2021229605A1 (en) * | 2020-05-14 | 2021-11-18 | Dr. Reddy's Laboratories Limited | Process for preparation of savolitinib and its intermediates |
| CN116209754A (zh) * | 2020-09-28 | 2023-06-02 | 科德克希思公司 | 用于合成手性胺的工程化生物催化剂及方法 |
| WO2022133046A2 (en) * | 2020-12-16 | 2022-06-23 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| KR102659095B1 (ko) | 2021-01-08 | 2024-04-19 | 에이비온 주식회사 | 트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법 |
| CN113278019A (zh) * | 2021-05-31 | 2021-08-20 | 河南偶联生物科技有限公司 | 一种咪唑并[1,2-a]吡啶类化合物的合成方法 |
| WO2022266190A1 (en) | 2021-06-16 | 2022-12-22 | Blueprint Medicines Corporation | Substituted pyrimidinyl-pyrazoles as cdk2 inhibitors |
| CN117897384A (zh) | 2021-06-28 | 2024-04-16 | 缆图药品公司 | Cdk2抑制剂 |
| AU2023258030A1 (en) * | 2022-04-20 | 2024-10-17 | Engrail Therapeutics, Inc. | Gabaa receptor modulator salts, particles, and uses thereof |
| CA3261476A1 (en) | 2022-07-08 | 2024-01-11 | Astrazeneca Ab | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Combination with HGF Receptor Inhibitors for the Treatment of Cancer |
| CA3264745A1 (en) * | 2022-07-29 | 2024-02-01 | Baylor College Of Medicine | NEUROTROPHIC TYROSINE KINASE RECEPTOR (NTRK) INHIBITORS AND ASSOCIATED METHODS |
| CN115611802B (zh) * | 2022-12-02 | 2023-03-14 | 北京迪泰医药科技有限公司 | 一种3-乙酰基-2-氯吡啶的合成方法 |
| US20260216148A1 (en) * | 2023-01-04 | 2026-07-30 | Blueprint Medicines Corporation | Cdk2 inhibitors |
| GB202300923D0 (en) * | 2023-01-20 | 2023-03-08 | Macfarlan Smith Ltd | Novel polymorphic forms of savolitinib |
| WO2024263860A1 (en) * | 2023-06-22 | 2024-12-26 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| WO2026145483A1 (zh) * | 2024-12-31 | 2026-07-09 | 深圳市塔吉瑞生物医药股份有限公司 | 靶向c-MET蛋白降解靶向嵌合体类化合物及其组合物及用途 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| US5977134A (en) * | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| EP1082324A4 (en) * | 1998-05-26 | 2002-01-02 | Merck & Co Inc | IMIDAZOPYRIDINE COMPOUNDS AS THROMBINE INHIBITORS |
| JP2000119250A (ja) * | 1998-08-11 | 2000-04-25 | Takeda Chem Ind Ltd | 環状アミド化合物、その製造法、中間体及び除草剤 |
| EP1615931A1 (en) | 2003-04-09 | 2006-01-18 | Biogen Idec MA Inc. | Triazolopyrazines and methods of making and using the same |
| US7122548B2 (en) | 2003-07-02 | 2006-10-17 | Sugen, Inc. | Triazolotriazine compounds and uses thereof |
| JP2007516180A (ja) * | 2003-07-02 | 2007-06-21 | スゲン，インコーポレイティド | ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類 |
| AU2004274403A1 (en) | 2003-09-03 | 2005-03-31 | Aventis Pharmaceuticals Inc. | 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds |
| NZ553267A (en) | 2004-07-27 | 2010-09-30 | Sgx Pharmaceuticals Inc | Pyrrolo-pyridine kinase modulators |
| MX2007002050A (es) | 2004-08-18 | 2007-03-29 | Pharmacia & Upjohn Co Llc | Compuestos de triazolopiridina. |
| KR20070104936A (ko) | 2005-02-16 | 2007-10-29 | 아스트라제네카 아베 | 화합물 |
| CN101119996A (zh) * | 2005-02-16 | 2008-02-06 | 阿斯利康(瑞典)有限公司 | 化学化合物 |
| US7728017B2 (en) * | 2005-11-30 | 2010-06-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Met and uses thereof |
| RS55630B1 (sr) | 2005-12-21 | 2017-06-30 | Janssen Pharmaceutica Nv | Triazolopiridazini kao modulatori tirozin kinaze |
| NL2000613C2 (nl) * | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
| CA2651979A1 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Triazolopyridazine derivatives |
| PE20121506A1 (es) * | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| US7683060B2 (en) | 2006-08-07 | 2010-03-23 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
| NZ575548A (en) | 2006-09-18 | 2011-09-30 | Vertex Pharma | Heterocyclic inhibitors of c-Met and uses thereof |
| EA016527B1 (ru) * | 2006-10-23 | 2012-05-30 | ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. | Триазолопиридазиновые модуляторы протеинкиназ |
| BRPI0717320A2 (pt) | 2006-10-23 | 2013-10-22 | Sgx Pharmaceuticals Inc | Triazóis bicíclicos como moduladores de proteína cinase |
| GEP20125658B (en) | 2006-11-22 | 2012-10-10 | Incyte Corp | Imidazotriazines and imidazo pyrimidines as kinase inhibitors |
| JP4785881B2 (ja) * | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| WO2008124848A1 (en) | 2007-04-10 | 2008-10-16 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| US8148369B2 (en) | 2007-05-10 | 2012-04-03 | Janssen Pharmaceutica Nv | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| WO2009105782A1 (en) * | 2008-02-21 | 2009-08-27 | Sequoia Pharmaceuticals, Inc. | Hiv protease inhibitor and cytochrome p450 inhibitor combinations |
| PE20091468A1 (es) | 2008-02-28 | 2009-10-22 | Novartis Ag | DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA |
| JP2011520986A (ja) | 2008-05-22 | 2011-07-21 | アムジエン・インコーポレーテツド | タンパク質キナーゼ阻害薬としての複素環類 |
| DE102008037790A1 (de) | 2008-08-14 | 2010-02-18 | Merck Patent Gmbh | Bicyclische Triazolderivate |
| UY32049A (es) | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| BR112012003262A8 (pt) * | 2009-08-12 | 2016-05-17 | Novartis Ag | compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação |
| IN2012DN01453A (enExample) * | 2009-08-20 | 2015-06-05 | Novartis Ag | |
| PT3511330T (pt) * | 2009-12-31 | 2020-12-24 | Hutchison Medipharma Ltd | Intermediário sintético útil na preparação de inibidores de triazolopiridina c-met |
| JP5960688B2 (ja) | 2010-05-17 | 2016-08-02 | インコゼン セラピューティクス プライベート リミテッド | プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物 |
-
2010
- 2010-12-30 PT PT191518240T patent/PT3511330T/pt unknown
- 2010-12-30 HU HUE19151824A patent/HUE052828T2/hu unknown
- 2010-12-30 PT PT131982241T patent/PT2719699E/pt unknown
- 2010-12-30 EP EP15170608.2A patent/EP2966075B1/en active Active
- 2010-12-30 CA CA2785749A patent/CA2785749C/en active Active
- 2010-12-30 CN CN201080065014.1A patent/CN102906092B/zh active Active
- 2010-12-30 BR BR112012016129-6A patent/BR112012016129B1/pt active IP Right Grant
- 2010-12-30 KR KR1020147010967A patent/KR101771299B1/ko active Active
- 2010-12-30 EP EP13198224.1A patent/EP2719699B1/en active Active
- 2010-12-30 ES ES20199091T patent/ES2927146T3/es active Active
- 2010-12-30 SM SM20200693T patent/SMT202000693T1/it unknown
- 2010-12-30 EA EA201691461A patent/EA030141B1/ru not_active IP Right Cessation
- 2010-12-30 CU CU20120101A patent/CU24167B1/es active IP Right Grant
- 2010-12-30 ME MEP-2015-150A patent/ME02211B/me unknown
- 2010-12-30 EP EP19151824.0A patent/EP3511330B1/en active Active
- 2010-12-30 MY MYPI2012002974A patent/MY179933A/en unknown
- 2010-12-30 ES ES19151824T patent/ES2840454T3/es active Active
- 2010-12-30 WO PCT/CN2010/080499 patent/WO2011079804A1/en not_active Ceased
- 2010-12-30 KR KR1020127019509A patent/KR101434766B1/ko active Active
- 2010-12-30 PL PL19151824T patent/PL3511330T3/pl unknown
- 2010-12-30 RS RS20150584A patent/RS54217B1/sr unknown
- 2010-12-30 CN CN201610437304.3A patent/CN106117248B/zh active Active
- 2010-12-30 MX MX2016001733A patent/MX386852B/es unknown
- 2010-12-30 SM SM20220371T patent/SMT202200371T1/it unknown
- 2010-12-30 PT PT201990918T patent/PT3795573T/pt unknown
- 2010-12-30 HU HUE13198224A patent/HUE025504T2/en unknown
- 2010-12-30 US US13/501,222 patent/US8987269B2/en active Active
- 2010-12-30 RS RS20201567A patent/RS61281B1/sr unknown
- 2010-12-30 PE PE2020001800A patent/PE20211094A1/es unknown
- 2010-12-30 CN CN201610432059.7A patent/CN106432225B/zh active Active
- 2010-12-30 HR HRP20221090TT patent/HRP20221090T1/hr unknown
- 2010-12-30 UA UAA201208929A patent/UA107822C2/ru unknown
- 2010-12-30 LT LTEP20199091.8T patent/LT3795573T/lt unknown
- 2010-12-30 PL PL20199091.8T patent/PL3795573T3/pl unknown
- 2010-12-30 EA EA201200951A patent/EA025466B1/ru not_active IP Right Cessation
- 2010-12-30 EP EP20199091.8A patent/EP3795573B1/en active Active
- 2010-12-30 RS RS20220854A patent/RS63612B1/sr unknown
- 2010-12-30 KR KR1020177022937A patent/KR101905350B1/ko active Active
- 2010-12-30 PE PE2012000903A patent/PE20130375A1/es not_active Application Discontinuation
- 2010-12-30 SI SI201032046T patent/SI3511330T1/sl unknown
- 2010-12-30 ES ES15170608T patent/ES2726152T3/es active Active
- 2010-12-30 ES ES13198224.1T patent/ES2546635T3/es active Active
- 2010-12-30 JP JP2012546344A patent/JP5337313B2/ja active Active
- 2010-12-30 MX MX2012007756A patent/MX336996B/es active IP Right Grant
- 2010-12-30 PE PE2016000292A patent/PE20160588A1/es unknown
- 2010-12-30 PH PH1/2012/501355A patent/PH12012501355A1/en unknown
- 2010-12-30 NZ NZ601128A patent/NZ601128A/en unknown
- 2010-12-30 DK DK13198224.1T patent/DK2719699T3/en active
- 2010-12-30 DK DK19151824.0T patent/DK3511330T3/da active
- 2010-12-30 DK DK20199091.8T patent/DK3795573T3/da active
- 2010-12-30 SI SI201031021T patent/SI2719699T1/sl unknown
- 2010-12-30 AU AU2010338712A patent/AU2010338712B2/en active Active
- 2010-12-30 SG SG2012044830A patent/SG181781A1/en unknown
- 2010-12-30 PL PL13198224T patent/PL2719699T3/pl unknown
- 2010-12-30 HU HUE20199091A patent/HUE059696T2/hu unknown
- 2010-12-30 EP EP10840591.1A patent/EP2519524A4/en not_active Withdrawn
-
2012
- 2012-04-10 US US13/501,224 patent/US8507487B2/en active Active
- 2012-06-14 IL IL220433A patent/IL220433B/en active IP Right Grant
- 2012-06-26 CL CL2012001752A patent/CL2012001752A1/es unknown
- 2012-06-28 GT GT201200220A patent/GT201200220A/es unknown
- 2012-06-29 EC EC2012012011A patent/ECSP12012011A/es unknown
- 2012-06-29 CO CO12109937A patent/CO6612235A2/es not_active Application Discontinuation
- 2012-06-29 NI NI201200118A patent/NI201200118A/es unknown
- 2012-06-29 DO DO2012000188A patent/DOP2012000188A/es unknown
- 2012-07-30 ZA ZA2012/05730A patent/ZA201205730B/en unknown
-
2013
- 2013-06-11 JP JP2013122502A patent/JP2013209418A/ja active Pending
-
2015
- 2015-01-21 US US14/601,674 patent/US20150368271A1/en not_active Abandoned
- 2015-06-23 AU AU2015203480A patent/AU2015203480B2/en active Active
- 2015-07-16 IL IL239997A patent/IL239997A/en active IP Right Grant
- 2015-09-08 HR HRP20150952TT patent/HRP20150952T1/hr unknown
- 2015-09-09 SM SM201500213T patent/SMT201500213B/xx unknown
- 2015-09-17 CY CY20151100816T patent/CY1118250T1/el unknown
-
2016
- 2016-04-04 JP JP2016074893A patent/JP6194046B2/ja active Active
- 2016-10-14 US US15/293,722 patent/US9956218B2/en active Active
-
2017
- 2017-08-10 JP JP2017155493A patent/JP6486999B2/ja active Active
-
2018
- 2018-04-04 US US15/945,324 patent/US10512645B2/en active Active
-
2019
- 2019-02-20 JP JP2019028197A patent/JP6647434B2/ja active Active
- 2019-11-08 US US16/678,091 patent/US10946014B2/en active Active
-
2020
- 2020-12-17 HR HRP20202017TT patent/HRP20202017T1/hr unknown
- 2020-12-21 CY CY20201101206T patent/CY1123777T1/el unknown
-
2021
- 2021-02-03 US US17/248,688 patent/US11896592B2/en active Active
-
2022
- 2022-09-15 CY CY20221100615T patent/CY1125550T1/el unknown
-
2023
- 2023-12-13 US US18/538,151 patent/US20240139182A1/en not_active Abandoned
-
2024
- 2024-05-28 US US18/676,172 patent/US20250099462A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6612235A2 (es) | Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo | |
| CR20120362A (es) | Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo | |
| UY34484A (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
| CL2012002979A1 (es) | Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona. | |
| UY34342A (es) | ?derivados de pirrolopirimidina y purina?. | |
| PH12013500500A1 (en) | Fused heteroaryls and their uses | |
| CO6680644A2 (es) | Polipétidos de ralaxina modificados y sus usos | |
| CR20120158A (es) | Compuestos de diòxido de iminotiadiazina como inhibidores de bace, composiciones y su uso. | |
| UY34602A (es) | ?Derivados de bencimidazolil- e imidazopiridinil-metilamina? | |
| EP2526112A4 (en) | TARGET GENOMODIFICATION | |
| UY34472A (es) | Derivados modificados de 4-fenil-piridina | |
| EA201270619A1 (ru) | Применение бетанехола для лечения ксеростомии | |
| ME03766B (me) | Određeni amino-pirimidini, njihove kompozicije, i metode njihove upotrebe | |
| UY34167A (es) | Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos | |
| UY34817A (es) | Tienopirimidinas | |
| BR112015012907A2 (pt) | composição de cuidado pessoal | |
| CL2015003479A1 (es) | Métodos y composiciones de fermentación bacterial. | |
| UY34200A (es) | 3-(fluorovinil)pirazoles y su uso | |
| ECSP12011653A (es) | Derivados de n1-acil-5-fluoropirimidinona | |
| CL2012003083S1 (es) | Dibujo industrial de interfase de control | |
| CL2009001973S1 (es) | Mostrador. | |
| PA8849101A1 (es) | Procedimiento de preparación del hemifumarato de eplivanserina | |
| CL2011000970S1 (es) | Cepillo de dientes. | |
| TN2010000567A1 (fr) | المحطة الكهرمائية الشمسية | |
| TN2010000017A1 (fr) | مستحضر تجميلي دوائي |